Omega Fund Management, LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 14, 2024), Omega Fund Management, LLC reported 11 stock positions worth $155.0 million. Its top holding was Nuvation Bio (NUVB) at 33.0% of the portfolio, followed by Lexeo Therapeutics (LXEO, 23.8%) and Replimune (REPL, 15.8%). Compared with Q4 2023, it sold out of 3, added to 1 and reduced 5. The biggest buy was Lexeo Therapeutics (LXEO, shares +9%) and the biggest sale an exit from Spruce Biosciences (SPRB).
- Most Recent 13F
- Q2 2026
- Location
- Boston, MA
- CIK
- 0001637359
- Portfolio Value
- $155.0M (Q1 2024)
- SEC Filing
- 0000950123-24-005045 ↗ filed May 14, 2024
Holdings Value
Holdings 11 stocks · $155.0M
| NUVB Nuvation Bio Inc. | 33.05% | 14,072,340 | $51.2M | Reduce -6.6% |
| LXEO Lexeo Therapeutics Inc. | 23.83% | 2,355,904 | $36.9M | Add +9.2% |
| REPL Replimune Group Inc. | 15.82% | 3,001,319 | $24.5M | No change |
| ENGN Engene Holdings Inc. | 11.77% | 1,076,357 | $18.2M | Reduce -4.8% |
| SANA Sana Biotechnology Inc. | 5.44% | 843,750 | $8.4M | No change |
| MORF Morphic Holding Inc. | 3.63% | 159,846 | $5.6M | Reduce -48.4% |
| IKENA ONCOLOGY INC | 2.06% | 2,249,123 | $3.2M | No change |
| IMUX Immunic Inc. | 1.52% | 1,788,160 | $2.4M | No change |
| ENGENE HOLDINGS INC | 1.21% | 360,903 | $1.9M | Reduce -24.0% |
| SYRS Syros Pharmaceuticals Inc. | 0.87% | 251,270 | $1.3M | No change |
| KRON Kronos Bio Inc. | 0.80% | 955,866 | $1.2M | Reduce -75.0% |
Portfolio Sells Q4 2023 → Q1 2024
| SPRB Spruce Biosciences Inc. | Sold out | 0.00% | −5.13 |
| MORF Morphic Holding Inc. | Reduce -48.4% | 3.63% | −3.62 |
| KRON Kronos Bio Inc. | Reduce -75.0% | 0.80% | −3.06 |
| THRX Theseus Pharmaceuticals Inc. | Sold out | 0.00% | −2.33 |
| SNTI Senti Biosciences Inc. | Sold out | 0.00% | −0.10 |
| ENGENE HOLDINGS INC | Reduce -24.0% | 1.21% | +0.88 |
| ENGN Engene Holdings Inc. | Reduce -4.8% | 11.77% | +3.31 |
| NUVB Nuvation Bio Inc. | Reduce -6.6% | 33.05% | +14.61 |
Portfolio Buys Q4 2023 → Q1 2024
| LXEO Lexeo Therapeutics Inc. | Add +9.2% | 23.83% | +0.37 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 10 | $185.7M | BCAX, NUVB, KMTS, BBOT, BBNX |
| Q1 2026 | 10 | $163.1M | BCAX, NUVB, BBOT, KMTS, BBNX |
| Q4 2025 | 11 | $286.5M | NUVB, BBOT, BBNX, BCAX, KMTS |
| Q3 2025 | 12 | $222.4M | KMTS, BBNX, BBOT, BCAX, NUVB |
| Q2 2025 | 13 | $154.4M | BBNX, KMTS, UPB, NUVB, BCAX |
| Q1 2025 | 13 | $169.5M | KMTS, BCAX, BBNX, NUVB, REPL |
| Q4 2024Amended | 12 | $154.2M | BCAX, NUVB, UPB, REPL, LXEO |
| Q3 2024 | 11 | $160.0M | BCAX, NUVB, REPL, LXEO, ENGN |
| Q2 2024 | 11 | $135.0M | NUVB, LXEO, REPL, ENGN, ALMS |
| Q1 2024 | 11 | $155.0M | NUVB, LXEO, REPL, ENGN, SANA |